Research programme: monoclonal antibody therapeutics - Gmax Biopharm

Drug Profile

Research programme: monoclonal antibody therapeutics - Gmax Biopharm

Alternative Names: GMA 103; GMA 104; GMA 202

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gmax Biopharm
  • Class Analgesics; Antihyperglycaemics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus
  • Research Cancer

Most Recent Events

  • 01 Nov 2017 Research programme: monoclonal antibody therapeutics - Gmax Biopharm is available for licensing in World as of 01 Nov 2017. http://www.gmaxbiopharm.com/job.html
  • 01 Nov 2017 Preclinical trials of GMA 103 in Type-2 diabetes mellitus in China (Parenteral) (Gmax Biopharm pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top